News Coverage
The Partnership for Safe Medicines has been publishing information about the counterfeit drug problem around the world for more than a decade. With experts leading the organization and a committed and passionate set of writers and editors, our content is more in-depth than many other sources, which simply copy links to the news from other websites.
Stories about hundreds of thousands of counterfeit pills made with fentanyl in nine U.S. states.
A Miami man was charged with selling sketchy HIV medication to U.S. pharmacies; 47 people indicted for fentanyl pill trafficking in four separate investigations; stories about pressed pills in eight states, Ireland and Mexico.
Washington, DC (June 17, 2022) – Shabbir Safdar, executive director of The Partnership for Safe Medicines, released the following statement today: “The U.S. Senate Committee on Health, Education, Labor & Pensions’ 15-7 vote against Senator Sanders’ foreign drug importation amendment to S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, is…
Consumption of undeclared diclofenac could result in serious adverse events that include cardiovascular, gastrointestinal, renal, and anaphylaxis in patients taking concomitant NSAIDs and/or anticoagulants, in those who have allergies to diclofenac, or those with underlying illnesses. Consumption of undeclared dexamethasone may lead to severe and serious adverse events such as adrenal suppression, a disorder in which the adrenal glands do not produce enough hormones, and adverse consequences can range from limited adverse consequences to death.
Washington, D.C. (Updated June 13, 2022) – Shabbir Imber Safdar, executive director of the Partnership for Safe Medicines, released the following statement in advance of the Senate HELP Committee’s June 14th Executive Session. “The amendments offered to include foreign drug importation in S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, are…
So, what does all of this have to do with importing drugs from a friendly nation like Canada? The simple, inarguable fact is that, once we open up our drug supply, we can no longer ensure the safety of the products in it.
Instead of wasting time and money on dangerous and faulty importation proposals, Congress should encourage the FDA to speed up the drug approval process and reduce the cost of program and application fees for future drug development. In 2022, the application fee for a human drug application will cost $1.6 million for drugs that don’t require clinical data and $3.1 million for medicines that do need clinical data.
In this week’s news: A San Diego doctor pays for smuggling hydroxychloroquine to sell fake $4,000 COVID treatment kits; the British Medical Journal writes about black market sales of molnupiravir; Canadians warn about fake Xanax made with flualprazolam; and 14 more stories in 11 states.
While working to find a way to provide relief to patients at the pharmacy counter, American politicians again look to the idea of drug importation as a possible solution. Looking at all the evidence, the Partnership for Safe Medicines believes such plans will not only make no difference in reducing patient out-of-pocket costs, but will…
Watch our new ad: “Congress: Don’t invite global drug counterfeiters to the U.S. Drug Supply” As the pandemic upended our daily lives, illegally-imported counterfeit products flooded into our communities. Criminals all over the world moved quickly to exploit fear and take advantage of disrupted supply lines in March 2020. Americans were-and continue to be-deluged in…